Cypress Pharmaceutical, Inc.
All Topics
Find news about people
Find news on alumni of any org
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


Change Feed

News on Cypress Pharmaceutical, Inc.

... generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit http://www.pernixtx.com. About SILENORĀ® SILENORĀ® ...
... reduction of expenses incurred related to the in-process research and development at Cypress as certain of these projects were transferred to Breckenridge connected with the ...
... Breckenridge ANDA products secured from the September 2013 acquisition of certain Cypress Pharmaceutical, Inc. product assets. Breckenridge's Mefenamic Acid Capsules are AB rated to Ponstel ...
... excluding the impact of the stepped up basis of acquired inventory for Cypress, Hawthorn, and Somaxon, gross profit margin this quarter was 54%, compared to ...
... assets to Breckenridge Pharmaceutical, Inc. The divested assets are from the Cypress Pharmaceutical, Inc. subsidiary of Pernix and include 11 Abbreviated New Drug Applications (ANDAs) ...
... Inc. announced today that it has completed its acquisition of certain Cypress Pharmaceutical, Inc. product assets from Pernix Therapeutics. The assets include 11 Abbreviated New ...
... its sales force. Pernix markets its generic products through its wholly-owned subsidiaries, Cypress Pharmaceutical and Macoven Pharmaceuticals. The Company's wholly-owned subsidiary, Great Southern Laboratories, manufactures ...
Subscribe now for full coverage on Cypress Pharmaceutical, Inc.
Start My Free Trial